← Eichor
Study identifier: NCT06834152 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer

Condition: Localized Prostate Carcinoma · Prostate Cancer (Adenocarcinoma) · Prostate Hyperplasia  ·  Sponsor: University of Zurich

PhaseN/A
Planned participants75
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The aim of this phase II international multicenter study is to evaluate the safety, feasibility, and efficacy of CT or MRI-adaptive SBRT, delivered in five weekly fractions, in patients with newly diagnosed localized prostate cancer who have lower urinary tract symptoms and/or prostatic hyperplasia.

This description comes directly from the study's public registry record.

Talk to the study team

Radiation Oncology Study Office  ·  +41442554108  ·  RAO_akademischesoffice@usz.ch

Always discuss trial participation with your own doctor first.

Locations (3)

Klinik für Radioonkologie und Strahlentherapie, Universitätsklinikum HeidelbergHeidelberg, Baden-Wurttemberg, GermanyNot Yet Recruiting
Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum LMUMunich, Bavaria, GermanyNot Yet Recruiting
University Hospital Zurich, Department of Radio-OncologyZurich, Canton of Zurich, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06834152